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Blocompatibility of dialysis membranes: Effects of chronic comple-
ment activation. The ability of three dialysis membranes (cuprophane,
cellulose acetate, and polymethylmethacrylate) to activate comple-
ment was studied prospectively in ten chronic dialysis patients using
new and reused membranes. Patients were dialyzed for 1 month with
each type of membrane. New cuprophane membranes caused the most
intense activation, while polymethylmethacrylate (PMMA) surfaces
caused the least degree of complement activation. Reuse decreases the
capacity of the cuprophane membrane to activate complement but does
not significantly alter the capacity of cellulose acetate membranes. The
extent of complement activation paralleled the ability of these mem-
branes to induce neutropenia. Recurrent dialysis with new cuprophane
and cellulose acetate membranes leads to a decrease in pre-dialysis and
rebound leukocytosis" neutrophil count, as well as a more intense ac-
tivation of complement and an enhanced endogenous clearance of
products of complement activation. The clinical sequelae of recurrent
complement activation are discussed.
Biocompatibilite des membranes de dialyse: effets de l'activité chron-
ique du complement. La capacitC de trois membranes de dialyse
(cuprophane, acetate de cellulose, et polymCthylmethacrylate)
d'activer le complement a été étudiée prospectivement chez dix
dialyses chroniques en employant des membranes neuves ou déjà
utilisCes. Les malades ont été dialyses pendant I mois avec chaque
type de membrane. Les membranes neuves en cuprophane entraina-
ient l'activation Ia plus intense, tandis que les surfaces en polymeth-
ylmethacrylate (PMMA) étaient responsables du moindre degre
d'activation du complement. La rëutilisation diminue Ia capacité de Ia
membrane de cuprophane a activer Ic complement mais ne modifie pas
significativement celle des membranes en acetate de cellulose.
L'importance de l'activation complementCmique était parallele a Ia
capacité de ces membranes dinduire une neutropénie. Des dialyses
repetees avec des membranes neuves de cuprophane ou d'acétate de
cellulose conduisent a une baisse de Ia numeration des neutrophiles
predialytique et a Ia "hyperleucocytose de rebound," a une activation
plus intense du complement et a une stimulation de l'Climination
endogCne des produits de l'activation du complement. Les consé-
quences cliniques d'une activation rCpCtee du complement sont
discutées.
Recent studies confirm that the complement system is acti-
vated during hemodialysis [1, 21. This activation is more in-
tense with cuprophane membrane than cellulose acetate [3] or
polyacrylonitrile (PAN) membranes [1] and for cuprophane, it
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attenuates with reuse [4, 5]. However, to our knowledge, the
long-term effects of chronic activation of complement during
dialysis has not been studied.
To investigate the differences in the ability of different mem-
branes to activate complement, we initiated a prospective
study of complement activation in ten chronic hemodialysis pa-
tients, using three different hollow fiber membranes, namely
cuprophane, cellulose acetate, and polymethylmethacrylate
(PMMA) membrane dialyzers. The latter membrane is used in
Europe and Japan and is undergoing clinical trials in the United
States. By using the same patient population on dialyzers with
the same hollow fiber configuration and surface area, we were
able to highlight important differences between these mem-
branes in terms of their capacity to activate complement and
cause neutropenia, both acutely and chronically.
Methods
Ten long-term chronic hemodialysis patients undergoing 4-hr
maintenance hemodialysis periods three times each week were
chosen for the study. Informed consent was obtained. None of
the patients were known to have had recent or current symp-
toms of fluid overload or cardiorespiratory diseases, and none
were known to be sensitive to dialysis membrane materials. Pa-
tients were dialyzed according to their schedule in a facility
practicing reuse, and fluid was removed to achieve their re-
spective dry weight. Maximum blood flow was 300 50
mI/mm and dialysate flow was maintained at 500 mI/mm.
Each patient was dialyzed with three different hollow dialyz-
ers, namely, the HPF-l00 (Erika, New Jersey) using
cuprophane fibers, the CD-4000 (Cordis-Dow, California) using
cellulose acetate fibers, and the TORAY B2-150 (TORAY In-
dustries, Tokyo, Japan) using PMMA fibers. In the first part of
the study, each patient was dialyzed for 1 month, which
equated to 13 dialysis sessions, on each type of dialyzer using
only new, first-use dialyzers each time, and successively
changed to the other types of membrane dialyzer. The se-
quence of dialyzer membrane material was the following: cu-
prophane, cellulose acetate, and finally PMMA. All dialyzers
including new dialyzers were packed in a 2% solution of for-
maldehyde, rinsed and primed in the usual manner, and tested
to be free of formaldehyde by the modified Schiff reagent (so-
dium meta-bisulfite), which is sensitive to less than 4 g/ml of
formaldehyde [61. After each use, dialyzers were washed and
packed with 2% formaldehyde solution according to standard
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Fig. 1. Neutrophil Count during dialysis with
new cuprophane membrane (t indicates the
beginning of the new cuprophane dialyzer
phase, indicates end of new cuprophune
dialyzer phase).
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reuse practice. After termination of the new dialyzer phases of
the study, the same patients were then dialyzed with their own
reused dialyzers for another month on each type of reused
membrane.
Blood samples were drawn predialysis from the arteriove-
nous fistula of the patient, and then at 15, 90, and 240 mm af-
ter initiation of dialysis, simultaneously from the arterial (af-
ferent) and venous (efferent) lines of the dialyzer. Blood sam-
ples were drawn in EDTA tubes, centrifuged, and separated
immediately; samples were stored in duplicate polypropylene
tubes at —70°C until processing. Samples were thawed only
once for processing. Blood samples drawn from patients dur-
ing the reuse phase were all drawn during the third use of the
dialyzer. Blood samples for white blood cell (WBC) analysis
were also drawn simultaneously from the afferent and efferent
lines and differential WBCs were performed on 100 cells. Neu-
trophil counts taken from the efferent and afferent samples at
all sampling times were similar for all dialyzer membranes
tested. Neutrophil counts reported are those measured in af-
ferent samples.
Measurements of complement activation. Radioimmunoas-
say measurements of C3adesarg, C4adesarg, and C5adesarg
were carried out with commercial kits developed by the
Upjohn Company, Kalamazoo, Michigan, using techniques de-
veloped by Chenoweth and Hugh [7, 81 for RIA measurements
of C3adesarg and C5adesarg and by Gorski, Hugh, and Mul-
ler-Eberhard [9] for C4adesarg. Cross-reactivity of C3adesarg,
C4adesarg, and C5adesarg was estimated at less than 1% [8].
Total C3 was measured in pre-dialysis samples at the begin-
fling and end of each phase using radial immunodiffusion as-
say, by the endpoint technique (Kallestad Laboratories, Aus-
tin, Texas).
All values are reported as mean SEM. Statistical analysis
was done by the pair-wise two-tailed Student's t test.
Results
Initiation of dialysis using new cuprophane membranes re-
sults in a rapid decline of neutrophils from the pre-dialysis
value of 3.7 0.32 x I03 cells/mm3, such that by 15 mm, the
Beginning of phase
Pre 3.7 0.32 3.8 0.39 3.5 0.43
15 1.1 0.16 3.0 0.32 3.0 0.34
90 4.5 0.31 4.8 0.36 3.8 0.47
240 4.7 0.41 4.6 0.41 3.6 0.31
End of phase
Pre 2.9 0.37 3.2 0.36° 3.4 0.37
15 0.6 0.16b 2.5 0.27° 3.1 0.33
90 4.3 0.37 4.3 0.54 3.8 0.34
240 4.3 0.39° 4.3 0.52 4.1 0.35
a p 0.01, from the corresponding value at the beginning of phase.
h p 0.05, from the corresponding value at the beginning of phase.
P < 0.07, from the corresponding value at the beginning of phase.
neutrophil count in the circulation is 1.1 0.16 X iO
cells/mm3 or 30% of its pre-dialysis value (neutropenic phase);
thereafter, the neutrophil count increases, and 60 mm after ini-
tiation of dialysis the neutrophil count returns to approxi-
mately baseline level, and increases further to 4.7 0.41 x i0
cells/mm3 (127% its pre-dialysis value) at 4 hr (rebound leuko-
cytosis phase) (Fig. I and Table 1). Comparison of the cyclical
variation of neutrophils at the beginning and the end of the
month on new cuprophane dialyzers (Fig. 1) shows that the
pre-dialysis neutrophil count was significantly decreased from
a level of 3.7 0.32 x i03 cells/mm3 to a level of 2.9 0.37
x i0 cells/mm3 (P  0.01); furthermore, the extent of neu-
tropenic response appears to be greater with the nadir in neu-
trophil count as low as 0.6 0.16 x IO cells/mm3, or 20% its
pre-dialysis value; the number of neutrophils in the neutrophil-
ic phase is also lower (P 0.07, Table 1).
Dialysis using new cellulose acetate membranes and new
PMMA membrane dialyzers results in similar changes al-
though attenuated in magnitude, particularly for the PMMA
membrane. For example, the nadir in neutrophil count with the

























Table 1. Neutrophil counts during dialysis with new membranes(mean SEM) x l0/mm3







Table 2. Neutrophil Counts during dialysis with reused membranes
(mean SEM) 103/mm3
Time Cuprophane Cellulose acetate PMMA
Beginning of phase
Pre 3.3 0.32 2.9 0.31 2.5 0.49
IS 3.1 0.53 1.6 0.43 2.1 0.47
90 3.6 0.36 2.3 0.52 3.03 0.22
240 3.7 0.35 3.2 0.44 2.8 0.47
End of phase
Pre 3.2 0.47 1.9 0.37a 3.3 0.44"
15 2.7 0.43 1.6 0.45 3.16 0.55
90 3.4 0.45 2.2 0.56 3.33 0.69
240 3.4 0.33 3.1 0.45 3.47 0.38
P < 0.05, from
phase.
the corresponding value at the beginning of the
x
(Table 1), whereas the nadir in neutrophil count is only 85% its
pre-dialysis value for the PMMA membrane (Fig. 2), all occur-
ring at 15 mm after the initiation of dialysis. After I month of
dialysis on the new cellulose acetate membranes, changes simi-
lar to those seen with cuprophane membranes were observed.
Thus, there was a decrease in the pre-dialysis, nadir, and re-
bound neutrophil count, as seen in 'Fable 1. On the other hand,
for the PMMA membrane, neither the pre-dialysis value nor
the nadir in neutrophil count was significantly different from
the beginning to the end of the month (Fig. 2 and Table 1); in-
stead there was an increase in the maximum neutrophil count
at 240 mm.
During the reuse phase, the extent of neutropenia seen early
during dialysis was markedly attenuated for the cuprophane





































Fig. 2. Neutrophil count during dialysis with
PMMA membrane dialyzers. No significant
change was seen in these counts at the end of
the month.
Fig. 3. Effect of reuse on neutrophil counts.
All dialyzers were tested during the third use.
Symbols are: , indicates values obtained at
the beginning of the reuse phase; J, , indicates
values obtained at the end of the reuse phase;














Fig. 4. C3adesarg level for cuprophane
membrane dialvzers as a function of dialysis
time. Symbols are: ( , indicates beginning of
new cuprophane dialyzer phase; , indicates
C3adesarg level after 1 month of new
cuprophane membrane dialysis; •—•,
efferent sample; 0—0, afferent sample.
Fig. 5. C3adesarg level for cellulose acetate
membrane dialyzers as a function of dialysis
time. Symbols are: (1' and indicate the
beginning and end of 1 month of new cellulose
acetate dialyzers, respectively; I—•, effereni
sample; 0--C, afferent sample.
Dialysis time, minutes
fected with reuse; thus, during the third use at 15 mm, it was
still 54% of the predialysis value. For the PMMA membrane,
the extent of neutropenia and rebound leukocytosis was not
markedly different during the reuse phase and was similar to
the limited cyclical variation observed during the new dialyzer
phase of PMMA. Pre-dialysis neutrophil counts at the end of 1
month of reuse with each type of dialyzer, seen in Figure 3B
and Table 2, were not significantly different for the cuprophane
membrane, but were significantly lower for the cellulose ac-
etate dialyzers and significantly higher for PMMA membrane
240 dialyzers (P  0.05).
The C3adesarg level in simultaneously drawn efferent and af-
ferent samples of cuprophane dialyzers at the beginning of the
new dialyzer phase is shown in Figure 4. It is seen that at the
beginning of the phase on new cuprophane dialyzers, the
C3adesarg level rapidly rose after the initiation of dialysis, such
that by 15 mm, the concentration in the efferent sample was
4343 417 ng/ml (309% its pre-dialysis level). Thereafter, it
decreased, and was 176% and 115% its pre-dialysis level at 90
and 240 mm respectively after initiation of dialysis. However,
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15 90
Fig. 6. C3adesarg level for PMMA membrane dialyzers as a function
of dialysis time. Levels at the end and the beginning of I month were
identical. Symbols are: •—•, efferent sample; C--C, afferent sample.
membrane dialyzer, the minimum neutrophil count seen at 15
mm was 93% its pre-dialysis value (Fig. 3); similarly, the neu-
trophilic phase was also attenuated. However, the extent of
neutropenia for the cellulose acetate membrane was less af-
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Table 3. Pre-dialysis C3 level by radioimmunodiffusion assay (mean
SEM), mg/mi
Type of dialysis
membrane Beginning of month End of month
Cuprophane 124.3 14.1 103.5 11.0
Cellulose acetate 125.7 9.5 121.5 14.2
PMMA 96.5 21 107 20
even at 240 mm, the efferent concentration of C3adesarg was
significantly greater than its pre-dialysis value (P = 0.008). Ar-
terial (afferent) samples showed similar patterns, but lesser in
magnitude, and at 240 mm the C3adesarg level was not signifi-
cantly different from pre-dialysis value. Of interest is that the
difference in the simultaneously drawn C3adesarg level in the
arterial and venous samples is greatly in excess of what can be
accounted for by hemoconcentration at 15 and 90 mm (P 
0.03), indicating a continuous activation of complement up to
90 mm. However, at times beyond IS mm, the difference be-
tween the arterial and venous samples narrows, reflecting a
slower rate of activation and simultaneous endogenous clear-
ance of these biologically active products, and at 240 mm, the
difference between the afferent and efferent samples was not
statistically significant.
The comparison of efferent and afferent samples for
cuprophane at the beginning and the end of the month indicate
a widening difference between the efferent and afferent concen-
tration at the end of the month, both at IS and 90 mm (P
0.01). In addition, both the pre-dialysis and the afferent levels
at 240 mm was significantly lower at the end of the month than
at the beginning (P 0.05), suggesting a faster endogenous
clearance of C3adesarg after repetitive activation of comple-
ment during dialysis with new cuprophane membranes. For
cellulose acetate membranes (Fig. 5), the rate of decline of
C3adesarg level between 15 and 90 mm was also higher at the
end of 1 month on new cellulose acetate membranes, and the
differences between the efferent and afferent samples at 15 and
90 mm were also statistically significant at the end of the month
(P 0.01), whereas they were not significantly different at 90
mm at the beginning of the month. At 240 mm, the level of the
arterial (afferent) C3adesarg level was still significantly greater
than pre-dialysis values at the beginning of the month (P 
0.001), but was not significantly greater than the pre-dialysis
level at the end of the month (P = 0.1).
PMMA membranes induce transient and minimal activation
of complement, as shown by the lower rise in the efferent
C3adesarg concentration at 15 mm (190% its pre-dialysis value)
and by the lack of significant differences between efferent and
afferent samples at times beyond 15 mm, both at the beginning
and the end of the month (Fig. 6).
C4adesarg levels, measured on efferent and afferent samples
on each of the three new dialysis membranes, were not statis-
tically significant from pre-dialysis levels.
The only significantly elevated level of C5adesarg was found
in the efferent venous sample at 15 mm and was highest for
cuprophane membranes, 33.5 5.1 ng/ml, and was 17.7 2,2
ng/ml for cellulose acetate membranes. C5adesarg was un-
detectable for the PMMA membrane at all times. There was a
small increase, but not statistically significant, in the C5adesarg
levels at the end of the month for the 15-mm efferent samples.
The pre-dialysis C3 level at the beginning and end of each
month on new dialysis membranes is shown in Table 3. It is
seen that during the month on cuprophane, the pre-dialysis C3
level decreases, from 124.3 14.1 mg/mI to 103.5 11.0
mg/mi, remains stable during the cellulose acetate phase, and
increases during the PMMA phase. However, none of these
changes were statistically significant (P a 0.1).
Complement activation as measured by C3adesarg level was
considerably attenuated during reuse. The extent of activation
inversely correlated with the behavior of the neutrophil count.
Thus, the highest activation with reused membranes occurred
with cellulose acetate membranes and was 215% its pre-dial-
ysis value at 15 mm (Fig. 7). Complement activation remained
high for cellulose acetate membranes throughout the month on
reuse and was 239% its pre-dialysis value at 15 mm at the end
of the reuse phase. On the other hand, cuprophane mem-
branes showed a more marked attenuation, with the maximum
C3adesarg level at 15 mm only 133 and 149% its pre-dialysis
value at the beginning and the end of the cuprophane reuse
phase, respectively. PMMA membranes did not show any sig-
nificant change in their complement activating capacity with re-
use, which remained low. Thus, the maximum C3adesarg level
at 15 mm was still 152% its predialysis value at the beginning
of the reuse phase and 133% its pre-dialysis level at the end of
the reuse phase (P > 0.3).
C4adesarg and C5adesarg levels were not significantly dif-
ferent from the baseline for all reused membranes and at all
times measured.
Discussion
Complement activation represents one aspect of blood-ma-
terials interactions and may be considered an index of biocom-
patibility, because products of complement activation have
several biological actions, such as leukoaggregation, histamine
release from mast cells, and an increase in capillary pulmo-
nary permeability which may contribute to adverse clinical and
biochemical changes [10, 111. Indirect evidence also suggests
that chronic dialysis with complement activating surfaces may
be associated with increased morbidity and mortality of dial-
ysis patients [12—IS].
The results of this study confirm that complement activation
by new cuprophane and cellulose acetate membrane dialyzers
persists well into dialysis, as evidenced by the significant
arteriovenous differences in the C3adesarg level up to 90 mm
after the initiation of dialysis [1, 31. For PMMA membranes,
complement activation is least of the three membranes studied
and appears to attenuate early during dialysis, such that the dif-
ference between the efferent and afferent samples is not sta-
tistically significant except at 15 mm [16].
Comparison of the C3adesarg level at the beginning and the
end of the month on new cuprophane or cellulose acetate mem-
branes shows two distinct features. For both membranes, the
extent of activation is more pronounced at the end of the
month. For example, the peak C3adesarg level at 15 mm for
cuprophane membranes is 309% its pre-dialysis value at the be-
ginning of the month, and 471% its pre-dialysis value at the end
of the month. Similarly, for cellulose acetate membranes, the
Fig. 7. c3adesarg level for reused dialyzers.
All sampling done during the third reuse of
each dialyzer. Symbols are: t and indicate
beginning of the month and end of the month
values, respectively; •—•. cellulose acetate;
A--A, cuprophane; O--O, PMMA.
peak C3adesarg level is 342% and 615% pre-dialysis level at the
beginning and the end of the month, respectively.
Despite the greater extent of activation at the end of the
month, the rate of clearance of C3adesarg (as assessed by dif-
ferences in efferent and afferent samples and the lower pre-dial-
ysis value) is also greater at the end of the month for both
cuprophane and cellulose acetate membranes, suggesting en-
hanced endogenous clearances of these products. For ex-
ample, the ratio of the afferent to efferent sample at 90 mm at
a time when complement activation is minimal, decreases from
0.87 to 0.66 for cuprophane membrane and from 0.88 to 0.76
for cellulose acetate membranes (P 0.03), whereas it re-
mains approximately 1.0 for the PMMA membrane. Thus, re-
current dialysis with complement activating surfaces appears
to lead to a greater activation as well as enhanced clearance of
complement products, suggesting that assessment of comple-
ment activation during hemodialysis must be considered with
prior dialytic history.
The explanation of this phenomenon is not clear at present.
Both C3 and factor B are substrates for complement activation
via the alternative pathway and increased levels after 1 month
of repetitive activation of the complement system may explain
the greater extent of activation at the end of the month. How-
ever, C3 declines with repetitive complement activation, and
increases during the PMMA membrane phase. Depletion of the
inhibitory factors of this pathway such as Factors H or I (C3b
inactivator) may provide an explanation, but there is at pre-
sent no experimental evidence for such a postulate [17, 181.
The failure to detect a significant increase in C4adesarg level
during hemodialysis constitutes strong evidence that the clas-
sical pathway is not activated, because activation of this path-
way leads to the generation of approximately equimolar
amounts of C3adesarg and C4adesarg, while the affinity of mast
cell receptors for C4adesarg is several orders of magnitude
lower than that for C3adesarg [9, 10, 19]. Despite the evidence
for vigorous complement activation during dialysis, C5adesarg
was detected only at 15 mm after initiation of dialysis with
cuprophane or cellulose acetate membranes. The rapid and ir-
reversible binding of C5adesarg to specific receptors on neu-
trophils and monocytes [20], and its short half-life of less than
2 mm in the circulation [21], would preclude its detection at
times other than the maximum complement activation and as-
sociated maximum neutropenia. The differences between this
study and that of Chenoweth et al [I], reporting elevation of
C5adesarg at 240 mm, is difficult to explain at present.
Confirming previous studies [4, 5], reuse of these mem-
branes significantly attenuates the degree of neutropenia and
complement activation; however, the results of this study in-
dicate that the extent of attenuation depends on the type of
membrane considered. Thus, whereas the reuse of the
cuprophane membrane significantly decreases its ability to ac-
tivate complement and induce neutropenia, for cellulose ac-
etate membrane reuse affects its biocompatibility to a lesser de-
gree and this membrane, even in the reuse phase, leads to re-
current activation of complement and induces cyclicl varia-
tion in neutrophil count and a decrease in predialysis neu-
trophil count. The PMMA membrane's capacity to activate
complement remains low and unchanged with reuse.
The mechanism for the decrease in complement activation
during dialysis and the improved biocompatibility of
cuprophane with reuse is likely to be due to specific deposi-
tion of complement fragments such as C3b on the activating
surface and its subsequent inactivation [4, 22, 231, as well as
non-specific deposition of fibrin on dialyzer membrane sur-
faces [24]. Differences in biocompatibility between reused cel-
lulose acetate and cuprophane may also be due to differences
in the stability of the covalent binding of C3b to these surfaces
during the reuse procedure [3, 25].
The decrease in the pre-dialysis neutrophil count in conjunc-
tion with a decrease in the rebound leukocytosis after recur-
rent complement activation with new cuprophane and cellu-
lose acetate membranes as shown in this study may reflect a
decrease in the ability of the bone marrow to respond [26-29]
and/or a decrease in the half-life of neutrophils after degranu-
lation [30], which may be a factor in the clinical observation of
increased morbidity [121 and mortality [13] in patients using
new membrane dialyzers only, since infection accounts for a
substantial percentage of morbidity of dialysis patients [31]. A
decrease in the phagocytic abilities of the pre-dialysis neu-
trophil after recurrent complement activation (unpublished ob-
servation) may also play a synergistic role. Differences in the
ability of complement activating surfaces to induce a more pro-
nounced hypoxemia than noncomplement activating surfaces
[16, 321 may also explain the increase in intradialytic symp-
toms such as chest pain and back pain seen with new
cuprophane membranes [3, 14]; similarly, differences in mor-
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bidity of patients dialyzed with non-complement activating
membranes such as PAN and those dialyzed with cuprophane
may also he due to their respective differences in their ability
to activate complement [15].
In summary, different dialysis membranes show significant
differences in their ability to activate complement, an index of
biocompatibility [33]. Recurrent dialysis with complement ac-
tivating surfaces leads to a more pronounced pre-dialysis neu-
tropenia, a decrease in rebound leukocytosis and greater ac-
tivation, as well as enhanced clearance of complement prod-
ucts. Dialysis with reused membranes significantly attenuates
their ability to activate complement, albeit to different de-
grees, depending on the type of membrane. PMMA membrane
dialyzers appear to be the most biocompatible hollow fiber
membranes tested.
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